TY - JOUR T1 - Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of COVID-19 Spike pseudotype virus JF - bioRxiv DO - 10.1101/2020.06.22.164665 SP - 2020.06.22.164665 AU - Nan Wang AU - Shengli Han AU - Rui Liu AU - Liesu Meng AU - Huaizhen He AU - Yongjing Zhang AU - Cheng Wang AU - Yanni Lv AU - Jue Wang AU - Xiaowei Li AU - Yuanyuan Ding AU - Jia Fu AU - Yajing Hou AU - Wen Lu AU - Weina Ma AU - Yingzhuan Zhan AU - Bingling Dai AU - Jie Zhang AU - Xiaoyan Pan AU - Shiling Hu AU - Jiapan Gao AU - Qianqian Jia AU - Liyang Zhang AU - Shuai Ge AU - Saisai Wang AU - Peida Liang AU - Tian Hu AU - Jiayu Lu AU - Xiangjun Wang AU - Huaxin Zhou AU - Wenjing Ta AU - Yuejin Wang AU - Shemin Lu AU - Langchong He Y1 - 2020/01/01 UR - http://biorxiv.org/content/early/2020/06/22/2020.06.22.164665.abstract N2 - The pandemic coronavirus COVID-19 affected global health from the end of 2019 to 2020 and may challenge global health in the future. There have been reports of Chloroquine (CQ) and Hydroxychloroquine (HCQ) used in clinical treatment. In our study, we used CCK-8 stain, flow cytometry and immunofluorescent stain to evaluated the toxicity and autophagy of CQ and HCQ respectively on ACE2 high expressed HEK293T cells (ACE2hi cells). We further analysied the binding character of CQ and HCQ to ACE2 by molecular docking, surface plasmon resonance (SPR) assays and molecule docking, COVID-19 spike pseudotype virus was also taken to investigate the suppression viropexis effect of CQ and HCQ. Results showed that HCQ is slightly more toxic to ACE2hi cells than CQ, both CQ and HCQ could bind to ACE2, and they also exhibit equivalent suppression effect for the entrance of COVID-19 Spike pseudotype virus into ACE2hi cells. Our finding provides a theoretical and experimental basis for the clinical treatment of CQ and HCQ for COVID-19.Competing Interest StatementThe authors have declared no competing interest. ER -